Is Spinal Cord Stimulation Still Effective After One or More Surgical Revisions?


Journal

Neuromodulation : journal of the International Neuromodulation Society
ISSN: 1525-1403
Titre abrégé: Neuromodulation
Pays: United States
ID NLM: 9804159

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 09 01 2023
revised: 01 03 2023
accepted: 01 03 2023
medline: 10 7 2023
pubmed: 22 4 2023
entrez: 22 04 2023
Statut: ppublish

Résumé

Spinal cord stimulation (SCS) is burdened with surgical complications that may require one or several surgical revision(s), challenging its risk/benefit ratio and cost-effectiveness. Our objective was to evaluate its outcome and efficacy after one or more SCS surgical revisions. We identified and retrospectively analyzed 116 patients treated by tonic paresthesia-based SCS who experienced one or more complication(s) requiring at least one surgical revision. Data collected included initial indication, revision indication, number of revisions, and lead design (paddle or percutaneous). Outcome after SCS revision was evaluated by pain intensity decrease (comparing baseline and postrevision Numerical Rating Scale [NRS] scores) and percentage of patients reporting pain relief ≥50%. Outcome was analyzed according to the number of surgical revisions and the revision indications. Most of the patients (61%) underwent only one revision (mean delay after implantation 44 months). The most frequent causes of revisions were hardware dysfunction (32%), lead migration (23%), and infection (18%). Revision(s) repaired the SCS issue in 87% of the cases. One year after the first revision, 82% of the patients reported pain relief ≥50%, and the mean NRS decrease was 4.0 compared with baseline (p < 0.001). Benefit of SCS revision tended to decrease with the number of revisions but did not differ across revision indications. No serious surgical complications related to the revision occurred, except for three hematomas occurring after repeated revisions. Our data suggest that surgical revision of SCS system is safe and led to significant pain relief in most of the cases, provided that the initial indication was good and that the previous stimulation was effective. However, success of SCS revision decreases with the number of revisions.

Identifiants

pubmed: 37086218
pii: S1094-7159(23)00141-1
doi: 10.1016/j.neurom.2023.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1108

Informations de copyright

Copyright © 2023 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Aurelie Leplus (A)

Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Department of Neurosurgery, Fédération Hospitalo-Universitaire INOVPAIN, Nice, France; Université Côte d'Azur, Unité de Recherche Clinique Côte d'Azur, Nice, France.

Jimmy Voirin (J)

Department of Neurosurgery, Hopitaux Civils de Colmar, Colmar, France.

Emmanuel Cuny (E)

Department of Neurosurgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Marie Onno (M)

Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Department of Neurosurgery, Fédération Hospitalo-Universitaire INOVPAIN, Nice, France.

Maxime Billot (M)

Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery Lab, Poitiers University Hospital, Poitiers, France.

Philippe Rigoard (P)

Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery Lab, Poitiers University Hospital, Poitiers, France; Department of Neurosurgery, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

Denys Fontaine (D)

Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Department of Neurosurgery, Fédération Hospitalo-Universitaire INOVPAIN, Nice, France; Université Côte d'Azur, Unité de Recherche Clinique Côte d'Azur, Nice, France. Electronic address: fontaine.d@chu-nice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH